Results 181 to 190 of about 3,164,975 (245)

Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples

Journal of Clinical Virology, 2013
Andreas R Huber
exaly   +2 more sources

The Specificity of Anti‐HCV Supplementary Assays

Vox Sanguinis, 1995
AbstractA total of 920 samples from blood donors screened as anti‐HCV negative by two third‐generation screening assays (Ortho Diagnostics v3.0 and Murex Diagnostics VK48) were tested by two supplementary anti‐HCV assays, RIBA III (Ortho Diagnostics) and Western blot (Murex Diagnostics VK68).
A D, Kitchen, N V, Tucker
openaire   +2 more sources

The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.

Journal of Hepatology, 2018
BACKGROUND & AIMS The efficacy of direct-acting antivirals (DAAs) has dramatically changed the prognosis of patients with chronic hepatitis C. We aimed to evaluate the impact of DAA therapy on the composition of the liver transplant (LT) waiting list and
G. Crespo, N. Trota, M. Londoño, E. Mauro, C. Baliellas, L. Castells, J. Castellote, J. Tort, X. Forns, M. Navasa   +9 more
semanticscholar   +1 more source

Directly Acting Triple Drug Anti-HCV Therapy Induces Sustained Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study

The Lancet, 2015
Background Direct acting anti-HCV drugs have demonstrated a high cure rate and favorable tolerability. The development of shorter courses of therapy may improve affordability and adherence.
Anita Kohli, A. Osinusi, Z. Sims, Amy K. Nelson, Eric G. Meissner, L. Barrett, Dimitra Bon, Miriam M. Marti, R. Silk, Colleen Kotb, C. Gross, Tim A. Jolley, S. Sidharthan, Tess L. Petersen, K. Townsend, D'Andrea Egerson, R. Kapoor, E. Spurlin, M. Sneller, M. Proschan, E. Herrmann, Richard W. Kwan, Gebeyehu Teferi, R. Talwani, Gabbie Diaz, D. Kleiner, Brad J. Wood, J. Chavez, Stephen E. Abbott, W. Symonds, G. Subramanian, P. Pang, J. Mchutchison, M. Polis, A. Fauci, H. Masur, S. Kottilil   +36 more
semanticscholar   +1 more source

Resistance to anti-HCV protease inhibitors

Current Opinion in Virology, 2011
The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges.
Thompson, A.J., Locarnini, S.A., Beard, M.R.   +2 more
openaire   +3 more sources

Cyclosporine pharmacokinetics in anti‐HCV+ patients

Clinical Transplantation, 2004
Abstract: Background: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients. In Brazil, around 30% of patients awaiting kidney transplantation carry anti‐HCV antibodies. Previous observations suggest altered CsA pharmacokinetics in these patients.Methods: We conducted two pharmacokinetic studies.
Luciano, Wolffenbüttel, Débora D, Poli, Roberto C, Manfro, Luiz Felipe S, Gonçalves   +3 more
openaire   +2 more sources

Sensitivity of an anti‐HCV core peptide ELISA

Journal of Medical Virology, 1992
AbstractA newly developed antibody assay based on a synthetic peptide of 15 amino acids derived from the core region of the hepatitis C virus (HCV) genome was evaluated in serum and plasma panels of (A) 225 haemophiliacs and (B) 44 patients with chronic non‐A, non‐B (NANB) hepatitis, and in (C) sequential serum samples of 9 patients with transfusion ...
Bresters, D., Reesink, H. W., Cuypers, H. T., Jansen, P. L., Mauser-Bunschoten, E. P., van der Poel, C. L., Lelie, P. N.   +6 more
openaire   +2 more sources

False-Positive Anti-HCV in Biliary Cirrhosis

Annals of Internal Medicine, 1991
To the Editors: A high prevalence of anti-hepatitis C virus (HCV) antibodies detected by enzyme immunoassay (HCV-EIA, Ortho) (1) has been reported in patients with various liver diseases, particula...
C, Housset, C, Hirschauer, F, Degos
openaire   +2 more sources

Recent Highlights in the Synthesis of Anti-HCV Ribonucleosides

Current Medicinal Chemistry, 2014
Research on Hepatitis C Virus inhibitors has dramatically increased during the past few years. Actually, several classes of anti-HCV drugs, including NS3/4A protease inhibitors, NS5B polymerase inhibitors, NS4B protein to RNA binding inhibitors, and multifunctional viral protein NS5A inhibitors, are in different stages of development. The RNA dependent
PIPERNO, Anna, CORDARO, Massimiliano, SCALA, ANGELA, IANNAZZO, Daniela   +3 more
openaire   +3 more sources

Rationale for preoperative screening of anti-HCV antibody

Journal of Anesthesia, 1993
We investigated the incidence of the anti-HCV antibody and associated factors in 1,031 surgical patients who had received blood transfusion during or after operation from October 1988 to April 1991, at Kyushu University Hospital. One hundred fifteen patients (11.2%) were anti-HCV positive.
Y, Sakaguchi, S, Inaba, J, Yoshitake
openaire   +2 more sources